New study identifies potential target for treating diabetic cardiomyopathy

SAN DIEGO — Treatment with raludotatug deruxtecan (R-DXd) led to an “exciting” response rate among patients with heavily pretreated, platinum-resistant advanced ovarian cancer, according to

Af­ter a sec­ond re­view, the FDA ap­proved Zevra Ther­a­peu­tics’ treat­ment for Nie­mann-Pick dis­ease type C, a pro­gres­sive rare ge­net­ic dis­ease caused by the ac­cu­mu­la­tion of